Escitalopram
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Escitalopram: Repurposing Evaluation — Insufficient Data to Complete Assessment
One-Sentence Summary
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) widely used for depression and anxiety disorders. The TxGNN model returned no predicted new indications for this drug in the current Evidence Pack, and critical data including Health Canada regulatory records, safety warnings, and mechanism of action are absent — preventing a full repurposing assessment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in Evidence Pack (known use: major depressive disorder, generalized anxiety disorder) |
| Predicted New Indication | None generated by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — no predictions available |
| Canada Market Status | Not marketed (per Evidence Pack; see note below) |
| Number of DINs | 0 |
| Recommended Decision | Hold |
⚠️ Data Quality Note: The Evidence Pack records escitalopram as not marketed in Canada with 0 DINs. This appears inconsistent with known regulatory reality — escitalopram (Cipralex®, Lundbeck) is a well-established Health Canada–approved product. This discrepancy suggests a data ingestion or query failure that must be resolved before any assessment can proceed.
Why Prediction Rationale Cannot Be Assessed
The TxGNN model returned an empty predicted_indications list for escitalopram. Without a model-generated candidate indication, no repurposing hypothesis can be formally evaluated.
For context, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacological knowledge, escitalopram selectively inhibits the serotonin transporter (SERT), increasing synaptic serotonin concentrations. This mechanism underlies its established efficacy in major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Serotonergic pathways have been implicated in conditions beyond mood disorders — including chronic pain, irritable bowel syndrome, and premenstrual dysphoric disorder — which may represent plausible future TxGNN prediction targets. However, no specific repurposing claim can be made without model output.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for escitalopram is critically incomplete: TxGNN generated no predicted indications, Health Canada DIN records are missing despite the drug’s known market presence, and all safety data are absent. No meaningful repurposing evaluation can proceed under these conditions.
To proceed, the following is needed:
- Diagnose empty TxGNN output: Confirm whether the absence of predictions reflects a pipeline issue (e.g., DrugBank ID mapping failure for DB01175) or an expected model result; re-run the prediction pipeline if necessary
- Fix Health Canada data ingestion: Query Health Canada’s Drug Product Database (DPD) directly for escitalopram / Cipralex® to retrieve correct DIN records and market status
- Retrieve MOA and safety data: Pull mechanism of action, boxed warnings, contraindications, and drug interaction data from the DrugBank API (DB01175) and the Health Canada product monograph
- Re-generate Evidence Pack: Once data gaps are resolved, regenerate the full Evidence Pack (v5+) and re-run this evaluation workflow
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.